77.5 B+
NAD+
Also known as: Nicotinamide adenine dinucleotide, NAD
Strong Clinical Evidence Research Chemical
Research Evidence 90.0/100
Safety Profile 65.0/100
60 Clinical Trials
Unknown: 11 PHASE4: 6 PHASE3: 11 PHASE2, PHASE3: 1 PHASE2: 7 PHASE1, PHASE2: 2 PHASE1: 3 NA: 18 EARLY_PHASE1: 1
- The New Third Generation Video Laryngeal Mask Evaluation Unknown Phase COMPLETED Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.
- The Exploratory Study on the Baseline Level of NAD+/NADH in Peripheral Blood Samples of Different Gender and Age Groups of Healthy Adults. Unknown Phase UNKNOWN Shanghai Cell Therapy Group Co.,Ltd
- SARS-CoV-2 Nucleic Acid Detection Kit Clinical Performance Study Unknown Phase COMPLETED TransGen Biotech Co., LTD
- Morphofunctional, Gene, Inflammation Molecules and Oxidative Stress Analysis in Kidney Tissue of COVID-19 Patients Unknown Phase COMPLETED Instituto Nacional de Enfermedades Respiratorias
- Genetic Variants in Nicotinamide Adenine Dinucleotide (NAD) Synthesis Pathway Unknown Phase COMPLETED Mayo Clinic
Showing 5 of 60 trials.
20 Research Papers
- Shedding light on YfhS and YjlC: novel effectors of the NADH dehydrogenase activity of the electron transport chain in Bacillus subtilis. bioRxiv unknown
- Impact of acute blue light irradiation on the molecular clock and markers associated with photoaging in skin cell models. J Mol Med (Berl) unknown
- Post-COVID increase in N-methyl-2-pyridone-5-carboxamide (Met2PY) and N-methyl-4-pyridone-3-carboxamide (Met4PY) associates with inflammatory and endothelial activation markers. Nucleosides Nucleotides Nucleic Acids unknown
- Gemella morbillorum Promotes Colorectal Carcinogenesis: LPBDCP-Mediated Invasion Activates Ras Signaling and Destabilizes p53. Adv Sci (Weinh) unknown
- Double-Pronged NAD Preservation: Delaying Cellular Senescence and Initiating Musculoskeletal Regeneration. Aging Cell unknown
Showing 5 of 20 papers by citation count.
FDA Data
Not FDA-Approved
NAD+ has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.
Frequently Asked Questions
Is NAD+ FDA approved?
No, NAD+ has not been approved by the FDA for human therapeutic use. It is sold as a research chemical.
How many clinical trials has NAD+ been studied in?
NAD+ has been studied in 60 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for NAD+?
NAD+ has a CheckPeptides trust score of 77.5/100 (grade: B+). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026
Quick Facts
- Classification
- Coenzyme / metabolic cofactor
- Molecular Weight
- 663.4 Da
- PubChem
- CID 5892 ↗
- Regulatory Status
- N/A
Score Breakdown
Research Evidence 90.0/100
Safety Profile 65.0/100
Evidence Summary
- Clinical Trials
- 60
- Research Papers
- 20
- Trust Score
- 77.5/100
- Grade
- B+